- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Prices for Opioid Overdose Drug Are Rising Fast
What we're reading, May 17, 2016: prices for opioid overdose drug are soaring; Valeant expands discounts for heart drugs; and 41% of Republicans want to replace the Affordable Care Act with a single-payer system.
Drug price hikes are becoming all too familiar. Now, the price of naloxone, which is used to reverse an opioid overdose, is soaring, according to POLITICO. The Obama administration and Congress are pushing to make the drug more widely available, but over the last 2 years, the prices of some versions of naloxone have risen 17-fold. Despite the fact that new competitors have entered the market and there are now 5 versions available, prices continue to rise.
Valeant Pharmaceuticals is expanding discounts for a pair of heart drugs that had their prices raised after being purchased in April 2015. Hospitals will be eligible for a rebate ranging from 10% to 40% based on the volume of drugs bought, reported The Wall Street Journal. The announcement comes after Valeant came under heavy fire and faced questions from a Senate committee after raising the prices of Nitropress and Isuprel by 212% and 525%.
A surprisingly high percentage of Republicans are in favor of replacing the Affordable Care Act (ACA) with a single-payer system, or a federally funded program. According to The Washington Post, More than half of all Americans, including 41% of Republicans and Republican-leaning Independents, approve of a single-payer system, though it might be because their views of the ACA are so strongly negative that replacing it with anything seems appealing. As for Democrats, nearly 8 in 10 want to keep the ACA, but a large number of them would love a single-payer system.
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
